Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Antipyrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 3/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antipyrine SCHEMBL29826493 | 1.00 | NAPRT (0.69) | NAPRTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| Antipyrine SCHEMBL28220175 | 0.85 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL20452 | 0.83 | NAPRT (1.00) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL27595284 | 0.82 | NAPRT (0.78) | NAPRTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| Antipyrine SCHEMBL28445203 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL18260589 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL8995343 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL7020007 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL8736656 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| Antipyrine SCHEMBL9845605 | 0.82 | NAPRT (0.96) | NAPRTALDH1A1KDM4ESMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-15 | — | — | US | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| EP-1684725-A1 | NOVEL NIMESULIDE COMPOSITIONS | Elan Pharma International Limited (IE) | 2006-08-02 | — | — | EP | claimed |
| EP-1617816-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | Elan Pharma International Limited (IE) | 2006-01-25 | — | — | EP | claimed |
| WO-2005051356-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-06-09 | — | — | WO | claimed |
| WO-2005002542-A2 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2005-01-13 | — | — | WO | claimed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12508305-B2 | Compositions and methods for treating and/or preventing glycogen storage disease type III | DUKE UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| WO-1995016465-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALKYL POLYOXYALKYLENE CARBOXYLATES | SANDOZ LTD. (CH) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | NAPRT 61/4885ALDH1A1 3888/4885KDM4E 1888/4885 |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | NIM1K, NIT2, NCL | NAPRT 61/4885ALDH1A1 3888/4885KDM4E 1888/4885 |
| US-12508305-B2 | Compositions and methods for treating and/or preventing glycogen storage disease type III | GYS1, PYGM, RNGTT | NAPRT 1131/4885ALDH1A1 4390/4885KDM4E 410/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | NAPRT 768/4885ALDH1A1 900/4885KDM4E 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.